Sean Smith - Mar 2, 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NLTX	Stock Option (Right to Buy)	Award	$0	+80K		$0.00	80K	Mar 2, 2022	Common Stock	80K	$2.72	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	1/4 of the shares subject to the option will vest on March 2, 2023, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.